SOJA3

Boa Safra Sementes S.A. (SOJA3)

Boa Safra Sementes is the largest independent soybean seed producer in Brazil, headquartered in Formosa (Goiás). It operates in the production, processing, and sale of soybean seeds (and, more recently, corn and beans), as well as industrial seed treatment (TSI). It went public on the B3 in April 2021 (ticker SOJA3, Novo Mercado).

Sector: Food & Agribusiness · Share price: R$ 5.82 (close on Jul 21, 2026) · Dividend yield (12m): 5.11% · 52-week range: R$ 5.71 – 10.83

Full analysis of SOJA3 (produced by this site with AI, Jul 21, 2026)

Rating: 5.5/10 · Verdict: UNDER REVIEW · Estimated fair price: R$ 7.00 (range R$ 5.00–10.00)

SOJA3 is Brazil's leading soybean seed producer (a record 10% market share, record volume of 215,000 big bags in 2025, +34%), trading at 0.63x book value after falling ~67% from its 2023 high. The discount exists for concrete reasons: the adjusted EBITDA margin fell from 10% to 5.9% in 2025, net income attributable to controlling shareholders collapsed from R$ 93.5 mn to R$ 20.0 mn, and the cost of debt jumped 254% (R$ 132 mn in interest in 2025) after the ~R$ 1 bn CRA issuance at CDI+3%.

This is a leveraged turnaround inside an adverse agri cycle: a structural ~30% seed surplus in the market, a record rural credit crisis, and cash-strapped farmers migrating to farm-saved seed. On the positive side, the R$ 1.5 bn order book is a record for a first quarter, Chicago soybean prices have turned back up, and the Selic has started falling. Rating 5.5/10 — UNDER REVIEW: estimated fair price of R$ 7.00 (+17% upside), but confirming the thesis depends on the second-half 2026 margin. This is not a stock for income seekers; it's a recovery bet with high risk.

Overview

Picture a soybean farmer: before planting, they need to buy seed. Boa Safra is the largest independent seller of that seed in Brazil — of every 10 bags of certified soybean seed sold in the country, 1 is theirs. It's a real, market-leading business that grows in volume every year.

So why did the stock fall from R$ 18 (2023) to under R$ 6? Because selling more hasn't meant earning more. Brazil's farm sector is under strain: cheap grain through 2025, sky-high interest rates, and indebted farmers. A farmer without cash does two things that hurt Boa Safra: they delay the purchase and use "farm-saved seed" (kept from the previous harvest, avoiding payment for certified seed). The result: seed piled up across the whole market (~30% went unsold), selling prices fell, and the company's margin melted away. At the same time, the company borrowed R$ 1 billion to grow — and the interest on that debt eats up a large chunk of what's left over.

The market today is paying less for the company than its equity is worth on paper (0.63x). That could be an opportunity — if margins recover — or a fair price for the risk, if the farm-sector squeeze continues. That's exactly what the next two results (August and November 2026) will reveal.

Investment thesis

The SOJA3 thesis today is cyclical value with turnaround optionality, resting on three pillars: (i) genuine leadership — 10% market share, a distribution network of 996 distributors, 94% germination rate, and ready installed capacity (280,000 big bags) with no need for significant new capex; (ii) liquidation-level pricing — 0.63x book value, below even the most pessimistic sell-side target (Citi at R$ 6.50), with an active buyback of up to 4.95% of the free float; (iii) visible turnaround levers — a record R$ 1.5 bn order book, soybean prices recovering in Chicago (US$ 12.26/bushel), the Selic starting a rate-cutting cycle (14.25%, projected at 12.5% by the end of 2026), and a possible structural tailwind from Bill 1702/19 (royalty on farm-saved seed).

The counterweight is heavy: with ~27% of soybean area using uncertified seed and rural credit going through its worst crisis on record (1,990 judicial recovery filings in 2025, +56%), Boa Safra's pricing power stays flattened and the default risk on credit sales grows (bad-debt provisions jumped from R$ 0.6 mn to R$ 13 mn). The stock is cheap ON BOOK VALUE but expensive ON CURRENT EARNINGS (P/E of ~35x over depressed profit). Whoever buys in today is buying margin normalization before it shows up in the numbers — with the discount as the margin of safety and 2H26 as the judge.

Strengths

  • Nationwide scale leadership. Brazil's largest independent soybean seed producer: 10% market share (record), 215,000 big bags sold in 2025 (+34%), 996 distributors (+43%), and 320,000 contracted hectares for seed multiplication.
  • A rare book-value discount. P/B of 0.63x on shareholders' equity of R$ 1.35 bn (already cleaned of SNAG11). The market pays R$ 853 mn for a market leader that generated R$ 2.6 bn in revenue for the year.
  • Record order book. R$ 1.5 bn in orders at the end of 1Q26 — a record for a first quarter — gives unusual visibility into 2H26 deliveries.
  • Expensive debt, but well spread out. Only R$ 62 mn matures within 12 months; R$ 963 mn matures beyond 5 years (CRAs through 2042). Cash of R$ 777 mn in March. The problem is the COST (CDI+3%), not the schedule — and a falling Selic eases exactly that.
  • Diversification accelerating. New crops and services grew +88% in 2025 (R$ 292 mn); corn via Bestway already dominates the order book opening 2026. It gradually reduces reliance on soybeans.
  • Quality as a moat. Average germination rate of 94% since 2021 and proprietary TSI — in a crop season with erratic weather (like 2025/26, with less viable seed on the market), the solid player gains share.

Weaknesses

  • Profitability on the floor. Adjusted EBITDA margin of 5.9% (was 10% in 2024), controlling shareholders' net income of R$ 20 mn (was R$ 301 mn in 2023), and ROE of ~1.5%. The company is growing volume without converting it into profit.
  • Financial costs devouring earnings. R$ 132 mn in interest expense in 2025 (+254%) — nearly 7x controlling shareholders' net income. As long as the Selic stays high, the ~R$ 1.3 bn gross debt works against the shareholder.
  • No pricing power in the current cycle. A ~30% sector-wide seed surplus plus a cash-strapped farmer means falling average selling prices. EBITDA per big bag plunged from ~R$ 1,900 (2023) to ~R$ 1,100 (2025).
  • Credit sales in a record-default environment. Accounts receivable of R$ 773 mn (27% of gross revenue) in an agribusiness sector with judicial recovery filings at a historic peak. Bad-debt provisions have already jumped 20x (R$ 0.6 mn → R$ 13 mn) and could worsen.
  • Concentrated control and low liquidity. The founding Colpo family holds ~60% of shares; free float is ~41% with ~R$ 3.4 mn/day in turnover — large positions struggle to enter and exit, and minority shareholders have little influence.
  • 2025 payout above earnings. R$ 40 mn in interest on equity against R$ 20 mn in controlling shareholders' net income — nice for shareholders in the short term, but it eats into reserves and won't repeat without an earnings recovery.

Risks

  • Rural credit crisis deepening. This is risk #1. Rural credit delinquency jumped from 1.2% to 3.3% (stressed operations >15%, R$ 123 bn) and agribusiness judicial recovery filings hit a record (+56% in 2025). A broke farmer buys less certified seed, migrates to farm-saved seed, AND delays paying for what they already bought — a triple hit: volume, margin, and defaults.
  • Margin failing to recover in 2H26. If the sector's oversupply persists and the average selling price stays under pressure, the record R$ 1.5 bn order book turns into revenue WITHOUT profit — the market would read this as confirmation that the problem is structural, not cyclical, and the stock would lose its valuation argument.
  • Leverage and covenants. The trailing-12-month reading in March (6.5x net debt/EBITDA, at the seasonal peak) already drew analyst warnings about a breached covenant. The company took on another R$ 290 mn in working-capital financing in Jun/2026 (BOCOM BBM + Bank of China). If 2H doesn't deleverage the way the seasonal pattern dictates, renegotiations could get expensive — and there's a clause that blocks dividends in case of default.
  • Weather (La Niña/El Niño) in the 2026/27 crop season. Bad weather cuts twice: it reduces viable seed output (discards have already risen to 15%) and squeezes the customer-farmer's income. A strong El Niño could increase replanting demand, but with farmer margins under pressure — the net effect is uncertain.
  • Competition from farm-saved/pirated seed. 27% of Brazil's soybean area already uses uncertified seed. That's the business's permanent competitive ceiling: every real of squeeze on the farmer's pocket pushes area out of the formal market. Bill 1702/19 (royalty on farm-saved seed) could reverse this — but it depends on Congress, with no timeline.
  • Diversification execution. Corn (Bestway), wheat, beans and sorghum are growing fast (+88%), but they're still ~13% of revenue and their margins remain unproven. XP called 2025 'the cost of growth and diversification' — the return on these bets has yet to show up.

Scenarios

Otimista: The agri-cycle turnaround

Revenue of R$ 2.6-2.8 bn with a normalized margin generates EBITDA of R$ 220-280 mn and net income of R$ 90-140 mn. The market re-rates from 0.63x to ~1.0x book value. This is the scenario XP has maintained (target R$ 11.80) and the one BTG once priced in (R$ 12). Indicative price: R$ 10.00.

Base: Slow, partial recovery

Controlling shareholders' net income normalizes to around R$ 60-100 mn in 2026-2027. The stock leaves the ICU but without euphoria: it re-rates to 0.73-0.78x book value while the market waits for confirmation over another crop season. Dividends remain symbolic (minimum payout). Indicative price: R$ 7.00.

Pessimista: The squeeze turns into a crisis

Another year of near-zero profit or a loss. The book-value discount stops being a psychological floor (equity heavy in inventory and receivables from a farmer under stress is worth less in a liquidation) and the stock heads toward 0.45-0.50x P/B. Zero dividends; dilution risk if capital is needed. Indicative price: R$ 4.80.

Valuation

SOJA3 is the classic case where every multiple tells a different story: on current depressed earnings it's EXPENSIVE (P/E ~35x); on book value it's VERY CHEAP (P/B 0.63x); on normalized potential it trades at a moderate discount. Our approach: estimate "mid-cycle" earnings (neither the 2023 peak nor the 2025 trough) and cross-check three methods. The result converges on a range of R$ 6.20 to R$ 7.40, with a central point of R$ 7.00 — an upside of +17% over R$ 5.97, insufficient to compensate for the risk without signs confirming the margin. For reference, sell-side targets (end of 2026) range from R$ 6.50 (Citi) to R$ 12 (BTG), with XP at R$ 11.80 — all calculated BEFORE any eventual confirmation in 2H26.

  • P/B × normalized profitability: R$ 7.40 — Book value of R$ 9.59/share (Mar/26, ex-SNAG11). With ROE normalizing at 7-9% (still below the cost of capital), a fair P/B of 0.75-0.80x. The discount persists until ROE exceeds ~12%.
  • Normalized earnings × P/E: R$ 6.70 — Mid-cycle net margin of 4% on R$ 2.6 bn in revenue = ~R$ 105 mn in net income. A P/E of 9x (leveraged cyclical small cap) = R$ 945 mn in fair market value.
  • Normalized EV/EBITDA: R$ 6.20 — Normalized EBITDA of ~R$ 220 mn (8.5% margin) × 6x = an EV of R$ 1.33 bn, minus average net debt over the year (~R$ 450 mn, given the strong seasonality) = equity value of ~R$ 880 mn.
  • Reference: sell-side consensus: R$ 10.00 — Median of end-2026 targets: BTG R$ 12 · XP R$ 11.80 · Itaú BBA R$ 10 · Bradesco BBI R$ 9 · Citi R$ 6.50. All NEUTRAL except XP (buy). Used only as a sanity check, not included in the average.

Timing

Where we are in the cycle: probably near the operational bottom — but an agri-cycle bottom can last an entire additional crop season. The price (R$ 5.97) has already taken a 67% hit and trades below the market's most pessimistic target, Chicago soybean prices have turned upward, the Selic has started falling, and the order book is at a record. What's missing is the key piece: proof that the margin has come back. That arrives in two acts — the 2Q26 result (August, showing the direction of the order book and average price) and, most importantly, 3Q26 (November 2026), when ~44% of the year's revenue flows through the result. For those who want to position before the proof, the current price pays for the risk IF the position is small and the horizon is long; for those who'd rather pay more for more certainty, the objective trigger is the 3Q26 EBITDA margin returning to the 8%+ range.

Management — who runs the company

Management rating: 6.5/10

Boa Safra is run by the founding siblings: Marino Colpo handling day-to-day operations (CEO) and Camila Colpo Koch chairing the board — together, the family holds ~59% of the company. It's the classic owner-operator model with maximum alignment: the CEO holds ~26% of the shares in his own name, executive bonuses fell from R$ 2.8 mn to R$ 0.65 mn tracking the profit collapse (real pay-for-performance), and dilution from the stock plan is negligible (0.037%).

In 2025 the company professionalized its finance area: Felipe Marques (formerly of Olam, formerly of BrasilAgro) took over as dedicated CFO/Investor Relations Officer, and Patrícia Baceti (30 years in controllership — DASA, Itaú) joined as Head of Administration and Control, undoing the stacking of roles that had existed since the IPO. The board, renewed in April 2026, is 80% independent — with the former CEO of Syngenta Brazil and the former CEO of BrasilAgro among its members, an unusually strong résumé for an agribusiness small cap.

The caveats exist and aren't cosmetic: the decision to take on ~R$ 1 bn in CRAs at CDI+3% near the top of the Selic cycle was a costly capital-allocation mistake (R$ 132 mn in interest expense in 2025); the commercial director paid R$ 126 thousand under a settlement (Termo de Compromisso) with the CVM (2025) over trading shares during a blackout period — without admitting guilt, but a mark on conduct; and the volume of related-party transactions with the family (leases, grain supply, advances) calls for ongoing monitoring. Rating 6.5/10: operationally competent and highly aligned management, with real reservations about financial discipline and conduct.

  • Marino Stefani Colpo — CEO (Diretor-Presidente) · founder. Founder and controlling shareholder (~26% of shares in his own name). Business administrator with a specialization in financial markets (Northwestern/Chicago), more than 18 years in agribusiness, formerly of INTL FCStone. Took over the family business in 2009 and grew it from ~R$ 32 mn in revenue to an IPO in 2021 and R$ 2.6 bn in 2025.
  • Camila Stefani Colpo Koch — Chair of the Board of Directors · founder. Founder and controlling shareholder. Agronomist with a specialization in genetic improvement from Syngenta (France) and an MBA from FGV. At Boa Safra since 2010 — the company's technical seed expertise comes from her.
  • Felipe Pereira Marques — CFO and Investor Relations Officer (CFO/DRI). Economist and accountant, MBA from FGV and M&A studies at Wharton. More than 17 years across BankBoston/Itaú, Elektro, Olam International, and BrasilAgro. The arrival of a dedicated market CFO is a central piece of the post-IPO professionalization.
  • Patrícia Regina Baceti — Head of Administration, Control and Technology. 30 years in controllership, finance, and ESG — with stints at DASA, Orizon, and Itaú Unibanco. A senior hire that strengthened internal controls at a moment of margin squeeze and rising leverage.
  • Humberto Pimenta Martins Filho — Commercial Director. Agronomist, more than 17 years in agribusiness sales (Bayer, Los Grobo, Agrogalaxy). Point of attention: paid R$ 126 thousand under a settlement (Termo de Compromisso) with the CVM (2025) to close an investigation into share trading during a blackout period — without admitting guilt.
  • Glaube de Sousa Caldas — Director of Production and Operations. More than 16 years in agricultural management. Held the finance, IR, and control roles concurrently until the 2025 reorganization — now focused on the company's industrial core (seed processing and quality, with an average germination rate of 94%).

Delivered: nationwide leadership built organically (market share ~10%, 215,000 big bags in 2025, 996 distributors), well-integrated diversification M&A (Bestway in corn, Qualiseed), and competent defensive management through the 2025 crisis (cost cuts, opportunistic leasing of facilities from competitors that closed). The board was renewed in 2026 with 80% first-tier independent agribusiness names.

What fell short: the promised EBITDA margin didn't materialize (10% → 5.9%); the ~R$ 1 bn in leverage at CDI+3% was taken on at the worst possible moment and consumes nearly the entire result; and the R$ 40 mn interest on equity paid in Dec/2025 exceeded the year's net income — a shareholder nod that burns reserves. The acid test for current management is converting the record R$ 1.5 bn order book into margin in the second half of 2026.

Governance, control and liquidity

An owner-operator company: the founding Colpo family controls ~59% (Marino Colpo is CEO; Camila Colpo Koch chairs the board). That brings long-term alignment and agility — but also concentrated power: minority shareholders sit in the back seat. The counterweights, though, are unusually strong for an owner-operator company: Novo Mercado listing (100% common shares, tag-along rights), an 80% independent board renewed in April 2026 with heavyweight agro names (former CEO of Syngenta Brazil, former CEO of BrasilAgro), a statutory audit committee chaired by an independent member, and KPMG as auditor since 2017. The 4th buyback program (up to 4.95% of the free float, running through Nov/2026) signals that management sees the stock as cheap — an honest signal, since they're buying with their own cash at a tight moment.

  • Control: Colpo family ~59% (founders)
  • Free float: 41.26% — 57,700 individual shareholders
  • Average daily liquidity: ~R$ 3.4 mn/day
  • Listing: Novo Mercado (B3)
  • Buyback: 4th program, up to 4.95% of the float, expires Nov/2026
  • Audit: KPMG (since 2017)

Conclusion

Boa Safra is a legitimate, market-leading business — 10% of the soybean seed market, record volume and order book, proven quality (94% germination), and ready installed capacity. The problem in 2025 wasn't demand: it was PRICE (sector-wide seed surplus), FINANCIAL COST (R$ 132 mn in interest after R$ 1 bn in CRAs at CDI+3%), and the CUSTOMER (farmers in the worst credit crisis on record). The result: controlling shareholders' net income of R$ 20 mn and an EBITDA margin of 5.9% — half of what it used to be.
At R$ 5.97 (0.63x book value), the market already prices in much of this ordeal. Our valuation points to a fair price of R$ 7.00 (range R$ 5.00-10.00): there's upside, but it's not the wide-open bargain that P/B suggests in isolation — because a seed producer's equity is inventory and receivables from a stressed farmer, and because current earnings don't compensate for the capital invested. The gap between the scenarios (R$ 4.80 vs. R$ 10.00) will be decided by the second-half 2026 margin and the farmer's financial health in the 2026/27 crop season.
In one sentence: a recovery stock, for a small position, patient capital, and an eye on the November result. Those who already hold a position find reasons to hang on in the record order book and the turning macro backdrop. Those who don't can wait for margin confirmation in 3Q26 — paying perhaps 15-20% more in exchange for much less risk — or start a small position below R$ 6.00 knowing exactly what they're buying: a leveraged turnaround in the middle of a rural credit crisis.

Analysis produced by Rico aos Poucos with AI assistance, based on public filings (CVM), market data and news. Not investment advice.

Company details (CVM registry)

  • CNPJ (tax ID): 10.807.374/0001-77
  • CVM code: 25704
  • Sector: Food & Agribusiness
  • CVM category: Category A
  • Headquarters: FORMOSA / GO
  • Investor Relations Officer: Felipe Pereira Marques
  • Auditor: ERNST & YOUNG AUDITORES INDEPENDENTES S/S LTDA.
  • CVM registration: Apr 19, 2021
  • Status: ACTIVE

Dividends by year

  • 2025: R$ 0.4391 across 2 payment(s)
  • 2024: R$ 0.1409 across 1 payment(s)
  • 2023: R$ 0.9116 across 3 payment(s)
  • 2022: R$ 0.1037 across 2 payment(s)

Recent filings (CVM)

Data content (price, dividends and filings) plus in-house AI-assisted analysis; not investment advice. Sources: B3/Yahoo Finance and CVM (Brazilian SEC).